{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-24-000107","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.469372+00:00","generated_at":"2026-05-31T07:35:35.211230+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ClearPoint Neuro repays $10M convertible note early, eliminates all debt","bullets":["On Aug 23, 2024, fully repaid $10M convertible note held by PTC Therapeutics (orig. maturity Jan 2025).","Note was issued in Jan 2020; early repayment removes all debt from ClearPoint's balance sheet.","CEO says repayment avoids additional dilution and reflects confidence in the business.","PTC continues to support ClearPoint for Upstaza BLA submission to FDA for AADC deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-24-000107","json":"https://secwatch.observer/filing/0001285550-24-000107.json","markdown":"https://secwatch.observer/filing/0001285550-24-000107.md","text":"https://secwatch.observer/filing/0001285550-24-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000107/0001285550-24-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000107/clpt-20240826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:35:35.211230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}